Your browser doesn't support javascript.
loading
Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis.
Leader, Ross; Cowen, Jake; Rajeev, Surya Panicker.
Afiliação
  • Leader R; Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.
  • Cowen J; Acute Internal Medicine, University Hospital Aintree, Liverpool, UK.
  • Rajeev SP; Accident and Emergency Medicine, University Hospital Aintree, Liverpool, UK.
BMJ Case Rep ; 12(9)2019 Sep 19.
Article em En | MEDLINE | ID: mdl-31537607
Sodium glucose co-transporter-2 inhibitors (SGLT2-i) have become a popular therapeutic strategy in the management of hyperglycaemia in type 2 diabetes mellitus. The primary site of action of SGLT2-i is at the proximal renal convoluted tubule. They work by blocking SGLT2 receptors, sodium-dependent glucose co-transport molecules, which in turn prevents glucose reabsorption, facilitating glucosuria, improving glycaemic control as well as a moderate degree of weight loss. We report the case of a 51-year-old woman admitted to the acute medical unit with abdominal pain and vomiting, who was diagnosed with euglycaemic diabetic ketoacidosis secondary to recent initiation of an SGLT2-i medication (dapagliflozin). Clinicians should be aware of this rare side effect of SGLT2-i, to circumvent delays in patient management.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos Benzidrílicos / Cetoacidose Diabética / Inibidores do Transportador 2 de Sódio-Glicose / Glucosídeos Limite: Female / Humans / Middle aged Idioma: En Revista: BMJ Case Rep Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos Benzidrílicos / Cetoacidose Diabética / Inibidores do Transportador 2 de Sódio-Glicose / Glucosídeos Limite: Female / Humans / Middle aged Idioma: En Revista: BMJ Case Rep Ano de publicação: 2019 Tipo de documento: Article